This Is Why Shares Of Advaxis Moved Higher On Tuesday

Shares of

were trading higher by nearly 3 percent at $9.66 on Tuesday after the company

the establishment of a new scientific advisory board. Advaxis is a clinical-stage biotechnology company that develops cancer immunotherapties. The new scientific advisory board will "serve as a resource" to Advaxis in the development of its LM Technology platform, which includes clinical programs in HPV-associated cancers, HER2 expressing tumors and prostate cancer. The members of the new advisory board include Dr. Antoni Ribas, a professor of medicine, surgery, and molecular and medical pharmacology, Dr. Jedd Wolchock, chief of the Melanoma and Immunotherapeutics service, Dr. Nancy Freitag, a professor of Microbiology and Immunology, and Dr. Marc Lecuit, a microbiologist and infectious diseases physician. "The new members of our scientific team, all leaders in their respective fields, share with Advaxis the common goal of rapidly bringing new treatment options to patients in need," said Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. "Each brings invaluable experience to the team as we make decisions on where to expand and hone our research and clinical programs."